Urotensin II in chronic liver disease: In vivo effect on vascular tone

Scandinavian Journal of Gastroenterology

Volumn 43, Issue 1, 2008, Pages 103-109

  Kemp, William ^a,b   Roberts, Stuart ^a   Komesaroff, Paul A ^b   Zomer, Ella ^b   Krum, Henry ^b  

^a ALFRED HOSPITAL   (Australia)

^b MONASH UNIVERSITY   (Australia)

Author keywords

Cirrhosis; Haemodynamics; Portal hypertension; Urotensin II; Vasoactive mediators

Indexed keywords

UROTENSIN II;

ADULT; AGED; ARTICLE; BLOOD VESSEL REACTIVITY; BLOOD VESSEL TONE; CHRONIC LIVER DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; HUMAN; LASER DOPPLER FLOWMETRY; LIVER CIRRHOSIS; MALE; MICROCIRCULATION; PATHOPHYSIOLOGY; PORTAL HYPERTENSION; PRIORITY JOURNAL; SKIN BLOOD FLOW; VASODILATATION;

AGED; CHRONIC DISEASE; FEMALE; HUMANS; IONTOPHORESIS; LIVER CIRRHOSIS; MALE; MICROCIRCULATION; MIDDLE AGED; UROTENSINS; VASOMOTOR SYSTEM;

EID: 37549053297     PISSN: 00365521     EISSN: 15027708     Source Type: Journal    
DOI: 10.1080/00365520701580009     Document Type: Article

References (50)

1. Coulouarn Y, Lihrmann I, Jegou S, Anouar Y, Tostivint H, Beauvillain JC, et al. Cloning of the cDNA encoding the urotensin II precursor in frog and humans reveals intense expression of the urotensin II gene in motoneurons of the spinal cord. Proc Natl Acad Sci USA 1998;95:15803-8.
2. Pearson D, Shively JE, Clark BR, Geschwind I, Barkley M, Nishioka RS, et al. Urotensin II: a somatostatin-like peptide in the caudal neurosecretory system of fishes. Proc Natl Acad Sci USA 1980;77:5021-4.
3. Ames RS, Sarau HM, Chambers JK, Willette RN, Aiyar NV, Romanic AM, et al. Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14. Nature 1999;401:282-6.
4. Nothacker HP, Wang Z, McNeill AM, Saito Y, Merten S, O'Dowd B, et al. Identification of the natural ligand of an orphan G-protein-coupled receptor involved in the regulation of vasoconstriction. Nat Cell Biol 1999;1:383-5.
5. Liu Q, Pong SS, Zeng Z, Zhang Q, Howard AD, Williams DL Jr, et al. Identification of urotensin II as the endogenous ligand for the orphan G-protein-coupled receptor GPR14. Biochem Biophys Res Commun 1999;266:174-8.
6. Bern HA, Lederis K. A reference preparation for the study of active substances in the caudal neurosecretory system of teleosts. J Endocrinol 1969;45 Suppl:xi-xii.
7. Bern HA, Pearson D, Larson BA, Nishioka RS. Neurohormones from fish tails: the caudal neurosecretory system. I. "Urophysiology" and the caudal neurosecretory system of fishes. Recent Prog Horm Res 1985;41:533-52.
8. Richards AM, Charles C. Urotensin II in the cardiovascular system. Peptides 2004;25:1795-802.
9. Thanassoulis G, Huyhn T, Giaid A. Urotensin II and cardiovascular diseases. Peptides 2004;25:1789-94.
10. Affolter J, Webb DJ. Urotensin II: a new mediator in cardiopulmonary regulation? Lancet 2001;358:774-5.
11. Heller J, Schepke M, Neef M, Woitas R, Rabe C, Sauerbruch T. Increased urotensin II plasma levels in patients with cirrhosis and portal hypertension. J Hepatol 2002;37: 767-72.
12. Totsune K, Takahashi K, Arihara Z, Sone M, Ito S, Murakami O. Increased plasma urotensin II levels in patients with diabetes mellitus. Clin Sci (Lond) 2003;104:1-5.
13. Totsune K, Takahashi K, Arihara Z, Sone M, Satoh F, Ito S, et al. Role of urotensin II in patients on dialysis. Lancet 2001;358:810-1.
14. Ng LL, Loke I, O'Brien RJ, Squire IB, Davies JE. Plasma urotensin in human systolic heart failure. Circulation 2002; 106:2877-80.
15. Richards AM, Nicholls MG, Lainchbury JG, Fisher S, Yandle TG. Plasma urotensin II in heart failure. Lancet 2002;360:545-6.
16. Russell FD, Meyers D, Galbraith AJ, Bett N, Toth I, Kearns P, et al. Elevated plasma levels of human urotensin-II immunoreactivity in congestive heart failure. Am J Physiol Heart Circ Physiol 2003;285:H1576-81.
17. Cheung BM, Leung R, Man YB, Wong LY. Plasma concentration of urotensin II is raised in hypertension. J Hypertens 2004;22:1341-4.
18. Gray GA, Jones MR, Sharif I. Human urotensin II increases coronary perfusion pressure in the isolated rat heart: potentiation by nitric oxide synthase and cyclooxygenase inhibition. Life Sci 2001;69:175-80.
19. Bottrill FE, Douglas SA, Hiley CR, White R. Human urotensin-II is an endothelium-dependent vasodilator in rat small arteries. Br J Pharmacol 2000;130:1865-70.
20. MacLean MR, Alexander D, Stirrat A, Gallagher M, Douglas SA, Ohlstein EH, et al. Contractile responses to human urotensin-II in rat and human pulmonary arteries: effect of endothelial factors and chronic hypoxia in the rat. Br J Pharmacol 2000;30:201-4.
21. Douglas SA, Sulpizio AC, Piercy V, Sarau HM, Ames RS, Aiyar NV, et al. Differential vasoconstrictor activity of human urotensin-II in vascular tissue isolated from the rat, mouse, dog, pig, marmoset and cynomolgus monkey. Br J Pharmacol 2000;131:1262-74.
22. Lim M, Honisett S, Sparkes CD, Komesaroff P, Kompa A, Krum H. Differential effect of urotensin II on vascular tone in normal subjects and patients with chronic heart failure. Circulation 2004;109:1212-4.
23. Sondermeijer B, Kompa A, Komesaroff P, Krum H. Effect of exogenous urotensin-II on vascular tone in skin microcirculation of patients with essential hypertension. Am J Hypertens 2005;18:1195-9.
24. Affolter JT, Newby DE, Wilkinson IB, Winter MJ, Balment RJ, Webb DJ. No effect on central or peripheral blood pressure of systemic urotensin II infusion in humans. Br J Clin Pharmacol 2002;54:617-21.
25. Wilkinson IB, Affolter JT, de Haas SL, Pellegrini MP, Boyd J, Winter MJ, et al. High plasma concentrations of human urotensin II do not alter local or systemic hemodynamics in man. Cardiovasc Res 2002;53:341-7.
26. Bohm F, Pernow J. Urotensin II evokes potent vasoconstriction in humans in vivo. Br J Pharmacol 2002;135:25-7
27. Bellentani S, Tiribelli C, Saccoccio G, Sodde M, Fratti N, De Martin C, et al. Prevalence of chronic liver disease in the general population of northern Italy: the Dionysos Study. Hepatology 1994;20:1442-9.
28. Newby DE, Jalan R. Urotensin II: better than somatostatin for portal hypertension? Hepatology 2000;31:1201-2.
29. Shah V. Cellular and molecular basis of portal hypertension. Clin Liver Dis 2001;5:629-44.
30. Kemp W, Roberts SK, Krum H. Urotensin II: a vascular mediator in health and disease. Curr Vascr Pharmacol 2005; 3:159-68.
31. Abdelrahman AM, Pang CC. Involvement of the nitric oxide/L-arginine and sympathetic nervous systems on the vasodepressor action of human urotensin II in anesthetized rats. Life Sci 2002;71:819-25
32. Lacza Z, DWB. Urotensin-II is a nitric oxide-dependent vasodilator in the pial arteries of the newborn pig. Life Sci 2006;78:2763-6.
33. Lin L, Ding WH, JiangW, Zhang YG, Qi YF, Yuan WJ, et al. Urotensin-II activates L-arginine/nitric oxide pathway in isolated rat aortic adventitia. Peptides 2004;25:1977-84.
34. Zhang AY, Chen YF, Zhang DX, Yi FX, Qi J, Andrade-Gordon P, et al. Urotensin II is a nitric oxide-dependent vasodilator and natriuretic peptide in the rat kidney. Am J Physiol Renal Physiol 2003;285:F792-8.
35. Cahill PA, Redmond EM, Sitzmann JV. Endothelial dysfunction in cirrhosis and portal hypertension. Pharmacol Ther 2001;89:273-93.
36. Douglas SA, Tayara L, Ohlstein EH, Halawa N, Giaid A. Congestive heart failure and expression of myocardial urotensin II. Lancet 2002;359:1990-7.
37. Hood SG, Watson AM, May CN. Cardiac actions of central but not peripheral urotensin II are prevented by beta-adrenoceptor blockade. Peptides 2005;26:1248-56.
38. Watson AM, May CN. Urotensin II, a novel peptide in central and peripheral cardiovascular control. Peptides 2004; 25:1759-66.
39. Gardiner SM, March JE, Kemp PA, Davenport AP, Bennett T. Depressor and regionally selective vasodilator effects of human and rat urotensin II in conscious rats. Br J Pharmacol 2001;132:1625-9.
40. Gardiner SM, March JE, Kemp PA, Bennett T. Bolus injection of human UII in conscious rats evokes a biphasic haemodynamic response. Br J Pharmacol 2004;143:422-30.
41. Douglas SA, Dhanak D, Johns DG. From "gills to pills": urotensin-II as a regulator of mammalian cardiorenal function. Trends Pharmacol Sci 2004;25:76-85.
42. Leonardo G, Arpaia MR, Del Guercio R, Coltorti M. Local deterioration of the cutaneous venoarterial reflex of the hand in cirrhosis. Scand J Gastroenterol 1992;27:326-32.
43. Seino Y, Ohki K, Nakamura T, Tsukamoto H, Takano T, Aramaki T, et al. Pathophysiological characteristics of cutaneous microcirculation in patients with liver cirrhosis: relationships to cardiovascular hemodynamics and plasma neurohormonal factors. Microvasc Res 1993;46:206-15.
44. Bircher A, de Boer EM, Agner T, Wahlberg JE, Serup J. Guidelines for measurement of cutaneous blood flow by laser Doppler flowmetry. A report from the Standardization Group of the European Society of Contact Dermatitis. Contact Dermatitis 1994;30:65-72.
45. Zeghal K, Geslin P, Maurel A, Lagrue G, Lhoste F. Laser-Doppler velocimetry: a new technic for evaluating of microcirculation. A reproducibility study. Presse Med 1986;15:1997-2000.
46. Stucker M, Heese A, Hoffmann K, Rochling A, Altmeyer P. Precision of laser Doppler scanning in clinical use. Clin Exp Dermatol 1995;20:371-6.
47. Sundberg S. Acute effects and long-term variations in skin blood flow measured with laser Doppler flowmetry. Scand J Clin Lab Invest 1984;44:341-5.
48. Okumura H, Aramaki T, Katsuta Y, Terada H, Satomura K, Akaike M, et al. Regional differences in peripheral circulation between upper and lower extremity in patients with cirrhosis. Scand J Gastroenterol 1990;25:883-9.
49. Roddie IC, Wallace WF. Methods for the assessment of the effects of drugs on the arterial system in man. Br J Clin Pharmacol 1979;7:317-23.
50. Leifeld L, Clemens C, Spengler U, Sauerbruch T, Heller J. Intrahepatic urotensin II expression is down-regulated in liver cirrhosis. J Hepatology 2005;42(Suppl 2):69.